Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXN5003 in Healthy Participants
NCT07549750Phase 1Not yet recruiting
- Sponsor
- Helixon
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HXN5003 in atopic dermatitis (AD) (8 cohorts), sponsored by Helixon. Primary endpoint: Safety and tolerability of HXN5003 at Day 197. Planned start May 2026; status: not yet recruiting.
02
Drugs
HXN5003
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07549750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549750.